Panacea Biotec received a long-term loan commitment of up to $20 million from the U.S. International Development Finance Corporation (DFC) to expand its manufacturing capacity for the EasySix® hexavalent vaccine, anticipating a demand of 19 million doses in 2025 and over 100 million by 2030.